Trastuzumab Deruxtecan in HER2 Mutated Advanced NSCLC

Safety Results

DESTINY-Lung01

HER2-activating mutation cohort Intent-to-treat population (N = 91) Dose = 6.4 mg/kg

	n (%)	
Any adverse event	91 (100)	
Treatment-related adverse event	88 (97)	
Adverse event leading to dose reduction	31 (34)	
Adverse event leading to discontinuation of therapy	23 (25)	

AEs in >20% of patients, n (%)						
	Any grade	Grades 1-2	Grade 3	Grade 4	Grade 5	
Nausea	69 (75.8)	61 (67.1)	8 (8.8)	0	0	
Fatigue	55 (60.4)	49 (53.9)	6 (6.6)	0	0	
Vomiting	42 (46.2)	37 (40.7)	5 (5.5)	0	0	
Alopecia	42 (46.2)	42 (46.2)	0	0	0	
Diarrhea	37 (40.7)	34 (37.4)	2 (2.2)	1 (1.1)	0	
Constipation	34 (37.4)	34 (37.4)	0	0	0	
Anemia	33 (36.3)	23 (25.3)	10 (11.0)	0	0	
Decreased appetite	32 (35.2)	32 (35.2)	0	0	0	
Neutropenia	32 (35.2)	15 (16.5)	14 (15.4)	3 (3.3)	0	
Leukopenia	21 (23.1)	17 (18.7)	4 (4.4)	0	0	
Weight decreased	21 (23.1)	19 (20.9)	2 (2.2)	0	0	
Pneumonitis	19 (20.9)	14 (15.4)	4 (4.4)	0	1 (1.1)	

HER2, human epidermal growth factor receptor 2; AEs, adverse events. Li BT et al. *N Engl J Med*. 2022;386:241-251.

Trastuzumab Deruxtecan in HER2 Mutated Advanced NSCLC

Safety Results: Interstitial Lung Disease (ILD)

DESTINY-Lung01

Adjudicated Drug-Related ILD				
	6.4 mg/kg (n = 91)			
Any grade, n (%)	24 (26.4)			
Grade 1	3 (3.3)			
Grade 2	15 (16.5)			
Grade 3	4 (4.4)			
Grade 4	0			
Grade 5	2 (2.2)			
Median duration of disease, weeks (range)	43 (24-94)			


Trastuzumab deruxtecan withdrawn in 16 patients and interrupted in 8 patients because of adjudicated ILD.

DESTINY-Lung02

Adjudicated Drug-Related ILD					
	5.4 mg/kg (n = 101)	6.4 mg/kg (n = 50)			
Any grade, n (%)	6 (5.9)	7 (14.0)			
Grade 1	3 (3.0)	1 (2.0)			
Grade 2	2 (2.0)	6 (12.0)			
Grade 3	1 (1.0)	0			
Grade 4	0	0			
Grade 5	0	0			
Cases resolved, n (%)	3 (50.0)	1 (14.3)			
Median time to onset of first adjudicated ILD, days (range)	67.5 (40-207)	41.0 (36-208)			

Trastuzumab Deruxtecan in HER2 Mutated Advanced NSCLC

Management of Interstitial Lung Disease (ILD)



Additional adverse events associated with dose reductions or treatment interruptions: Neutropenia, febrile neutropenia, thrombocytopenia, left ventricular dysfunction

Additional adverse event associated with permanent discontinuation: Patients with LVEF 40%-45% and absolute decrease from baseline 10%-20% who do not recover to within 10% from baseline after a 3-week treatment interruption

HER2, human epidermal growth factor receptor 2; LVEF, left ventricular ejection fraction. ENHERTU (fam-trastuzumab deruxtecan-nxki). Prescribing information. Daiichi Sankyo, Inc.; Revised Nov 2022.